van der Werf T - Search Results

1

Rifampicin and moxifloxacin for tuberculous meningitis.

Akkerman O, Pranger A, van Altena R, van der Werf T, Alffenaar JW. Akkerman O, et al. Among authors: van altena r, van der werf t. Lancet Infect Dis. 2013 Jul;13(7):568-9. doi: 10.1016/S1473-3099(13)70101-4. Lancet Infect Dis. 2013. PMID: 23809221 No abstract available.

2

Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.

Alffenaar JW, Kosterink JG, van Altena R, van der Werf TS, Uges DR, Proost JH. Alffenaar JW, et al. Ther Drug Monit. 2010 Feb;32(1):97-101. doi: 10.1097/FTD.0b013e3181cc6d6f. Ther Drug Monit. 2010. PMID: 20042919 Clinical Trial.

3

Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.

Alffenaar JW, van Altena R, Harmelink IM, Filguera P, Molenaar E, Wessels AM, van Soolingen D, Kosterink JG, Uges DR, van der Werf TS. Alffenaar JW, et al. Clin Pharmacokinet. 2010 Aug;49(8):559-65. doi: 10.2165/11532080-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20608757 Clinical Trial.

4

Dosing ethambutol in obese patients.

Alffenaar JW, van der Werf T. Alffenaar JW, et al. Among authors: van der werf t. Antimicrob Agents Chemother. 2010 Sep;54(9):4044; author reply 4044-5. doi: 10.1128/AAC.00412-10. Antimicrob Agents Chemother. 2010. PMID: 20716782 Free PMC article. No abstract available.

5

Clarithromycin significantly increases linezolid serum concentrations.

Bolhuis MS, van Altena R, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW. Bolhuis MS, et al. Antimicrob Agents Chemother. 2010 Dec;54(12):5418-9. doi: 10.1128/AAC.00757-10. Epub 2010 Sep 13. Antimicrob Agents Chemother. 2010. PMID: 20837753 Free PMC article. No abstract available.

6

Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity.

Warmelink I, ten Hacken NH, van der Werf TS, van Altena R. Warmelink I, et al. Br J Nutr. 2011 Feb;105(3):400-8. doi: 10.1017/S0007114510003636. Epub 2010 Sep 28. Br J Nutr. 2011. PMID: 20875187

7

Nutritional status and vitamin D3 during antimicrobial treatment.

Warmelink I, van Altena R, ten Hacken N, van der Werf T, van der Veer E. Warmelink I, et al. Among authors: van altena r, van der werf t, van der veer e. Lancet. 2011 Apr 23;377(9775):1407-8; author reply 1408. doi: 10.1016/S0140-6736(11)60576-X. Lancet. 2011. PMID: 21515160 No abstract available.

8

Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis.

Pranger AD, Kosterink JG, van Altena R, Aarnoutse RE, van der Werf TS, Uges DR, Alffenaar JW. Pranger AD, et al. Ther Drug Monit. 2011 Jun;33(3):350-4. doi: 10.1097/FTD.0b013e31821b793c. Ther Drug Monit. 2011. PMID: 21544017

9

Immunology in tuberculosis: challenges in monitoring of disease activity and identifying correlates of protection.

van Altena R, Duggirala S, Gröschel MI, van der Werf TS. van Altena R, et al. Curr Pharm Des. 2011;17(27):2853-62. doi: 10.2174/138161211797470228. Curr Pharm Des. 2011. PMID: 21834760 Review.

10

Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis.

Alsaad N, van Altena R, Pranger AD, van Soolingen D, de Lange WC, van der Werf TS, Kosterink JG, Alffenaar JW. Alsaad N, et al. Eur Respir J. 2013 Aug;42(2):504-12. doi: 10.1183/09031936.00114812. Epub 2012 Oct 25. Eur Respir J. 2013. PMID: 23100498 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

478 results

Search Page